Panel Attempts Thrombosis Prevention In Taxus Labeling, Clears Seven Sizes
This article was originally published in The Gray Sheet
Executive Summary
Labeling for Boston Scientific'sTaxus paclitaxel-eluting stent should highlight the need for patients to take an anti-platelet and aspirin regimen for the first six months to prevent blood clots, FDA's Circulatory System Devices Panel recommends
You may also be interested in...
Taxus Breezes Through Panel On Cypher Drag, Possibly Raising Data Bar
The FDA Circulatory System Devices Panel endorsed Boston Scientific's proposed ARRIVE 2,000-patient, five-year Taxus postmarket study with no additional conditions beyond proposals made by the company
Taxus Breezes Through Panel On Cypher Drag, Possibly Raising Data Bar
The FDA Circulatory System Devices Panel endorsed Boston Scientific's proposed ARRIVE 2,000-patient, five-year Taxus postmarket study with no additional conditions beyond proposals made by the company
Thrombosis Events May Be Clarified By e-CYPHER Data Expected In February
FDA's public health notification related to adverse events for J&J/Cordis' Cypher is intended to generate further data collection for the drug-eluting stent rather than raise undue concern over clotting issues, the agency says